November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
24 citations
,
July 2005 in “Journal of the American Academy of Dermatology” A woman's eyelashes grew thicker and longer after taking topiramate, but returned to normal when she stopped the medication.
4 citations
,
March 2024 in “Journal of the American Academy of Dermatology” Clinical signs don't match inflammation levels in lichen planopilaris and frontal fibrosing alopecia.
3 citations
,
June 2023 in “Plastic & Reconstructive Surgery” The 2-step surgery effectively treats stable follicular vitiligo with high patient satisfaction and no major complications.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
2 citations
,
June 2024 in “Journal of Clinical Medicine” Alopecia Areata can affect nails, often improving on its own, but JAK inhibitors may help.
2 citations
,
September 2021 in “Anais Brasileiros de Dermatologia” Increased sunscreen use may be linked to frontal fibrosing alopecia in Hispanic females.
1 citations
,
June 2025 in “Frontiers in Immunology” Higher IgE levels may play a role in alopecia areata, especially in males, children, and severe cases.
January 2026 in “Contemporary Clinical Dentistry” VKHD can include rare oral symptoms like discolored teeth.
December 2025 in “Cosmetics” New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
January 2025 in “Medical Research Archives” A new classification and scoring system is needed for alopecia areata to better assess severity.
July 2024 in “International Journal of Molecular Sciences” The inhibitor DPP can promote hair growth.
April 2024 in “Pharmaceuticals” Bimatoprost helps with hair growth and eye conditions but can be costly and have side effects.
The study concluded that Frontal fibrosing alopecia can affect younger people, is often missed in men, and may be autoimmune-related.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
November 2025 in “Journal of Clinical Medicine” Alopecia areata patients should have eye check-ups due to increased risk of eye problems.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
November 2024 in “Psychology Health & Medicine” Psychological therapies may improve quality of life for people with alopecia areata.
2 citations
,
September 2025 in “Journal of Dermatological Treatment” Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
136 citations
,
July 2014 in “Proceedings of the National Academy of Sciences of the United States of America” FGF5 gene mutations cause unusually long eyelashes by affecting hair growth regulation.
23 citations
,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Tailored treatments for alopecia areata are recommended based on severity and patient needs.
9 citations
,
January 2023 in “Journal of Clinical Medicine” The FFA-QLI is a reliable tool for assessing quality of life in women with severe Frontal Fibrosing Alopecia.
4 citations
,
October 2019 in “Skin Appendage Disorders” Gefitinib can cause hair and eyebrow darkening.